Gilead Sciences stock analysis
Gilead Sciences passes 2 of 6 fundamental tests, a score of 3/10. On the daily chart it is in an uptrend, RSI 63, 3% below its 52-week high: uptrend, no fresh entry: wait for a pullback or breakout. Its own volatility puts the likely range at $144.59–$168.72 a month from now and $119.55–$204.07 in a year (68% bands). The last two days of news lean bullish (2 positive, 0 negative stories).
Fundamentals 3/10
- Market cap
- $193.7 B
- P/E · forward
- — · 15.7
- PEG · P/B
- 2.3 · 16.4
- ROE · net margin
- -21% · -11%
- Revenue · earnings growth
- +10% · —
- Debt / equity
- 223%
- Dividend · beta
- 2.1% · 0.3
- Next results
- 29 Oct 2026
- ✕ ROE above 15%
- ✕ Net margin above 10%
- ✓ Revenue growing over 10%
- ✕ Debt/equity under 100%
- ✓ Positive free cash flow
- ✕ PEG under 2
Swing technicals (daily)
- Trend
- up · 50d above 200d
- RSI(14)
- 63
- 20 / 50 / 200-day avg
- $149.97 / $146.84 / $138.03
- 20-day breakout
- above $160.51 · below $142.60
- ATR(14)
- $3.80 (2.4% a day)
- 52-week range
- $114.02 – $160.51
- Return 3m · 6m · 1y
- +17% · +13% · +27%
What the price could do
| In | Likely range (68%) |
|---|---|
| 1 mo | $144.59 – $168.72 (-7% / +8%) |
| 3 mo | $136.65 – $178.53 (-13% / +14%) |
| 6 mo | $129.28 – $188.70 (-17% / +21%) |
| 1 year | $119.55 – $204.07 (-23% / +31%) |
Analysts (26): buy, mean target $159.85 (+2%)
From its own volatility (27% a year), no drift assumed: what its swings allow, not a forecast.
Gilead Sciences news · last two days
News lean: Bullish · 2 up · 0 down- 18h agoGilead’s HIV Prevention Business Just Topped $1 Billion A Quarter. What Comes Next?Trefis
- 18h agoStocktwits Biotech Dealmaker: Gilead, AstraZeneca And Roche Chase Pipeline Expansion Over BuyoutsStocktwits
- 22h agoGilead Sciences Insider Sold Shares Worth $468,660, According to a Recent SEC FilingMT Newswires
- 45h agoGilead Sciences (GILD) Rises Higher Than Market: Key FactsZacks
- 46h agoGilead and Cardinal Health Stocks Jump to Record Highs. Why Healthcare Is on a Tear.Barrons.com
- 46h agoGilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026Business Wire
- 2d agoCan Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?Zacks
- 2d agoGilead and Vir forge $1.9bn pact to develop next-gen T-cell engagersPharmaceutical Technology
- 2d agoGilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should KnowZacks
- 2d agoWhat iShares Biotechnology ETF (IBB) Sold: Gilead Leads on Oct. 13GuruFocus.com
Its order flow and footprint, the AI read of every headline, the expected move, and your own holdings beside it, with your broker connected.
Information and analytics for education only, not investment advice or a recommendation to buy or sell. Alephix Intelligence is not registered with SEBI as an investment adviser or research analyst. Prices may be delayed; figures come from public market data.